Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients With Coronavirus Disease 2019 and Primary Antibody Deficiency.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 34746954.
- Also identified by DOI 10.1093/infdis/jiab554 and PMC identifier 8689914.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Previous reports highlighted the efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific monoclonal antibodies (mAbs) against coronavirus disease 2019. We conducted a prospective study on the clinical outcome and antiviral effects of mAbs added to standard of care therapy in SARS-CoV-2-infected patients with primary antibody defects. Median time of SARS-CoV-2 quantitative polymerase chain reaction (qPCR) positivity was shorter in 8 patients treated with mAbs (22 days) than in 10 patients treated with standard of care therapy only (37 days, P=.026). Median time of SARS-CoV-2 qPCR positivity from mAb administration was 10 days. The SARS-CoV-2 mAbs treatment was effective and well tolerated in patients with primary antibody defects.
Medical subject headings
- Antibodies, Viral
- Common Variable Immunodeficiency
- Primary Immunodeficiency Diseases
- SARS-CoV-2
- COVID-19 Drug Treatment